Literature DB >> 8677403

Sample size determination in stratified trials to establish the equivalence of two treatments.

J M Nam1.   

Abstract

When designing a trial to establish that a new treatment is as effective as a standard one, the conventional test procedure and sample size based on a null hypothesis of no difference between two treatments is inappropriate. Several authors have investigated test statistics and corresponding sample sizes based on the null hypothesis that the standard treatment is more effective than the new by at least some specific value for a single 2 x 2 table. This paper considers a trial that involves several 2 x 2 tables and presents an approximate formula for the sample size required to obtain a given power of a one-tailed score test for a null hypothesis of a specific common non-zero difference between two treatments across strata. I show that the sample size for a trial based on an unstratified test is always larger than that based on a stratified test when the design is balanced.

Mesh:

Year:  1995        PMID: 8677403     DOI: 10.1002/sim.4780141809

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  Randomization in clinical trials: stratification or minimization? The HERMES free simulation software.

Authors:  Hélène Fron Chabouis; Francis Chabouis; Florence Gillaizeau; Pierre Durieux; Gilles Chatellier; N Dorin Ruse; Jean-Pierre Attal
Journal:  Clin Oral Investig       Date:  2013-03-01       Impact factor: 3.573

Review 2.  Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer.

Authors:  Kohei Shitara; Junko Ikeda; Chihiro Kondo; Daisuke Takahari; Takashi Ura; Kei Muro; Keitaro Matsuo
Journal:  Gastric Cancer       Date:  2011-08-13       Impact factor: 7.370

3.  Rationale and design: telepsychology service delivery for depressed elderly veterans.

Authors:  Leonard E Egede; Christopher B Frueh; Lisa K Richardson; Ronald Acierno; Patrick D Mauldin; Rebecca G Knapp; Carl Lejuez
Journal:  Trials       Date:  2009-04-20       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.